Free Trial
NASDAQ:EVOK

Evoke Pharma Q3 2024 Earnings Report

Evoke Pharma logo
$4.69 +1.06 (+29.20%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$4.70 +0.01 (+0.32%)
As of 08/1/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Evoke Pharma EPS Results

Actual EPS
-$0.94
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Evoke Pharma Revenue Results

Actual Revenue
$2.65 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Evoke Pharma Announcement Details

Quarter
Q3 2024
Time
After Market Closes
Conference Call Date
Thursday, November 7, 2024
Conference Call Time
9:30AM ET

Upcoming Earnings

Evoke Pharma's Q2 2025 earnings is scheduled for Tuesday, August 12, 2025, with a conference call scheduled on Monday, August 11, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Evoke Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Evoke Pharma and other key companies, straight to your email.

About Evoke Pharma

Evoke Pharma (NASDAQ:EVOK), a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

View Evoke Pharma Profile

More Earnings Resources from MarketBeat